Lausanne

DGAP-News: R-LOGITECH S.A.M. with strong business performance in first quarter 2021

Retrieved on: 
Wednesday, May 5, 2021
Lausanne, Logitech, Logistics, Companies, Business, Articles

b'The issuer is solely responsible for the content of this announcement.\nMonaco, 5 May 2021 - R-LOGITECH S.A.M., one of the leading international ports infrastructure operators and logistics services providers in the natural resources sector, had a successful first quarter (Q1) 2021 despite a continuing challenging environment resulting from the COVID-19 pandemic.\nR-LOGITECH\'s liquidity position is strong, with a cash position of EUR 81.6 million and available unutilized long-term committed working capital lines of a further EUR 40.4 million.\nThe business performance is above budget and R-LOGITECH expects a strong full year 2021 with revenues and EBITDA above 2020 levels.\nR-LOGITECH is focused on handling essential commodities (fresh food, agribulk, fertilizer, sugar, paper and pulp) and its facilities are primarily dedicated to bulk and break bulk handling worldwide.\nR-LOGITECH had increased volumes in Europe, China and Africa and could expand all of its business lines.\nFr\xc3\xa9d\xc3\xa9ric Platini, CEO of R-LOGITECH: "We are pleased that our business model has again proven to be resilient under challenging circumstances and thank all our employees, clients and stakeholders for their outstanding contribution and support.

Key Points: 
  • b'The issuer is solely responsible for the content of this announcement.\nMonaco, 5 May 2021 - R-LOGITECH S.A.M., one of the leading international ports infrastructure operators and logistics services providers in the natural resources sector, had a successful first quarter (Q1) 2021 despite a continuing challenging environment resulting from the COVID-19 pandemic.\nR-LOGITECH\'s liquidity position is strong, with a cash position of EUR 81.6 million and available unutilized long-term committed working capital lines of a further EUR 40.4 million.\nThe business performance is above budget and R-LOGITECH expects a strong full year 2021 with revenues and EBITDA above 2020 levels.\nR-LOGITECH is focused on handling essential commodities (fresh food, agribulk, fertilizer, sugar, paper and pulp) and its facilities are primarily dedicated to bulk and break bulk handling worldwide.\nR-LOGITECH had increased volumes in Europe, China and Africa and could expand all of its business lines.\nFr\xc3\xa9d\xc3\xa9ric Platini, CEO of R-LOGITECH: "We are pleased that our business model has again proven to be resilient under challenging circumstances and thank all our employees, clients and stakeholders for their outstanding contribution and support.
  • We expect a strong full year 2021 in terms of volume and profitability and have a significant project- and deal pipeline.
  • "\nR-LOGITECH is one of the leading international ports infrastructure operators and logistics services providers in the natural resources sector.
  • The Group\'s primary business lines are port and terminal management, logistics and technology solutions.\nR-LOGITECH is a subsidiary of Monaco Resources Group S.A.M.\n'

Oculis Announces an Oversubscribed US$57 million Series C Financing

Retrieved on: 
Tuesday, May 4, 2021
Finance, Money, Economy, Corporate finance, Equity securities, Investment, Private equity

Phase 2 results in DME presented in 2020 showed efficacy and safety of OCS-01, and the first Phase 3 study is scheduled to commence during the second quarter 2021.

Key Points: 
  • Phase 2 results in DME presented in 2020 showed efficacy and safety of OCS-01, and the first Phase 3 study is scheduled to commence during the second quarter 2021.
  • Its mission is to foster industry leaders through converging resources globally.\nVI Partners is the longest-established Swiss VC firm.
  • For more than 20 years, VI Partners has been supporting innovative Healthcare and Technology companies, investing over CHF 250m in 55 ventures.
  • Wille AG is an active private equity investor in Life Science and Software venture companies as well as in Buy-Out companies.

AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, April 28, 2021
Vaccination, Vaccine, Virology

The Company also provided an overview of its recent clinical and corporate highlights and anticipated milestones for 2021.\nProf.

Key Points: 
  • The Company also provided an overview of its recent clinical and corporate highlights and anticipated milestones for 2021.\nProf.
  • Andrea Pfeifer, CEO of AC Immune SA, commented: \xe2\x80\x9cOur clinical and R&D accomplishments over the last quarter serve to strengthen our leadership in precision medicine for neurodegenerative diseases.
  • Encouraging clinical results from both of our Alzheimer\xe2\x80\x99s vaccine programs further reinforce our belief that early intervention, and ultimately prevention, using vaccines represents a key strategy in neurodegenerative diseases.
  • To enable this strategy, we are advancing our suite of novel diagnostics, such as our alpha-synuclein imaging agent, which recently entered the clinic in Parkinson\xe2\x80\x99s disease.

Logitech and Baidu Brian Partner to Transform the Way We Work Using AI and Voice

Retrieved on: 
Tuesday, April 13, 2021
Hardware, Audio, Video, Consumer electronics, Technology, Software, Companies, Computing, Human–computer interaction, Lausanne, Logitech, Computer mice, Baidu, Jaybird, Computer mouse, Streamlabs, Hardware, Audio, Video, Consumer electronics, Technology, Software, Companies, Computing, Human–computer interaction, Lausanne, Logitech, Computer mice, Baidu, Jaybird, Computer mouse, Streamlabs

The Logitech Voice M380 Wireless Mouse is powered exclusively by intelligent Baidu Speech technology* from Baidu Brain and features the comfort, performance and quality that users expect in a Logitech mouse.\nThis press release features multimedia.

Key Points: 
  • The Logitech Voice M380 Wireless Mouse is powered exclusively by intelligent Baidu Speech technology* from Baidu Brain and features the comfort, performance and quality that users expect in a Logitech mouse.\nThis press release features multimedia.
  • It comes from years of Baidu AI development and deployment and serves not only Baidu innovations, but also the entire industry as an open platform,\xe2\x80\x9d said Tian Wu, Baidu VP for AI department.
  • The Logitech Voice M380 Wireless Mouse offers precise cursor control, a comfortable rubber grip and up to 18-months battery life.\nThe Logitech Voice M380 Wireless Mouse with Baidu Speech Input* will be available exclusively in China beginning in April 2021.
  • Brands of Logitech include Logitech , Logitech G , ASTRO Gaming , Streamlabs , Ultimate Ears , Jaybird and Blue Microphones .

Media Publishares and VIDY announce partnership to develop NFT platform for fashion, arts and music community

Retrieved on: 
Thursday, April 8, 2021
Magazines, Mass media, Languages, Lausanne, Vidy, Vogue, NFT

SINGAPORE, Apr 9, 2021 - (ACN Newswire) - Media Publishares, publishers of Vogue, Esquire, Robb Report and Buro in Singapore announce a partnership with VIDY to launch and develop an NFT platform catering to the fashion, arts and music industry.

Key Points: 
  • SINGAPORE, Apr 9, 2021 - (ACN Newswire) - Media Publishares, publishers of Vogue, Esquire, Robb Report and Buro in Singapore announce a partnership with VIDY to launch and develop an NFT platform catering to the fashion, arts and music industry.
  • Having implemented VIDY's technology across Media Publishares' titles, the partnership between the two companies grew organically given their shared 'digital first' approach and innovative thinking.
  • The NFT platform slated to launch in Q3 of 2021 celebrates arts and culture within a 360-degree navigable virtual environment showcasing digital fashion, art, music and design.
  • VIDY has two native cryptocurrency tokens; VIDY and VIDYX, both of which are integral to the Vidy Rewarding, E-Commerce and NFT Ecosystem.

Logitech Announces Date for Release of Fourth Quarter and Full-Year Financial Results for FY 2021

Retrieved on: 
Tuesday, April 6, 2021
Hardware, Audio, Video, Consumer electronics, Technology, Software, Companies, Logitech, Lausanne, Free software, Nasdaq, Inc.

Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced that it expects to release FY 2021 fourth quarter and full-year financial results on Wednesday, April 28, 2021 at 9:00 p.m. Eastern Daylight Time and Thursday, April 29, 2021 at 3:00 a.m. Central European Summer Time.

Key Points: 
  • Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced that it expects to release FY 2021 fourth quarter and full-year financial results on Wednesday, April 28, 2021 at 9:00 p.m. Eastern Daylight Time and Thursday, April 29, 2021 at 3:00 a.m. Central European Summer Time.
  • Logitech designs products that have an everyday place in people's lives, connecting them to the digital experiences they care about.
  • Brands of Logitech include Logitech , Logitech G , ASTRO Gaming , Streamlabs , Blue Microphones , Ultimate Ears and Jaybird .
  • Logitech and other Logitech marks are trademarks or registered trademarks of Logitech Europe S.A. and/or its affiliates in the U.S. and other countries.

AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors

Retrieved on: 
Wednesday, March 31, 2021
Life sciences, Industry economics), Biotechnology, Sofinnova, Celgene, Amgen

LAUSANNE, Switzerland, March 31, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Alan Colowick, MD, MPH, a deeply experienced biotech and investment executive, was elected to the Companys Board of Directors at an extraordinary shareholders meeting today.

Key Points: 
  • LAUSANNE, Switzerland, March 31, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Alan Colowick, MD, MPH, a deeply experienced biotech and investment executive, was elected to the Companys Board of Directors at an extraordinary shareholders meeting today.
  • Dr Colowick has more than 20 years of industry experience in both large and emerging biotech companies, serving in a broad array of board, senior executive, clinical, regulatory, and commercial positions.
  • His extensive expertise in biotech from both industry and investment standpoints including from Celgene, Amgen and Sofinnova will bring an important perspective to our pipeline and corporate development.
  • Dr. Colowick commented: I am delighted to be elected to the Board of Directors at what is a particularly exciting moment for AC Immune.

AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer™ Platform to Enable Precision Medicine for Neurodegenerative Disease

Retrieved on: 
Wednesday, March 31, 2021
Branches of biology, Biology, Evidence-based medicine, Precision medicine, Systems biology, Neurodegeneration

LAUSANNE, Switzerland, March 31, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, will host an investor webinar today to discuss the unique benefits of the Companys innovative MorphomerTM technology platform, which generates first-in-class therapeutic and diagnostic candidates to power AC Immunes precision medicine approach for neurodegenerative diseases.

Key Points: 
  • LAUSANNE, Switzerland, March 31, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, will host an investor webinar today to discuss the unique benefits of the Companys innovative MorphomerTM technology platform, which generates first-in-class therapeutic and diagnostic candidates to power AC Immunes precision medicine approach for neurodegenerative diseases.
  • The live webinar begins at 10am ET and can be accessed here .
  • Prof.Andrea Pfeifer, Ph.D., CEO ofAC Immune SA, commented: Our industry-leading precision medicine approach aims to address the complexity and heterogeneity of neurodegenerative diseases by pairing highly selective and conformation-specific therapeutics with first- or best-in-class companion diagnostics.
  • AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimers disease, Parkinsons disease, and NeuroOrphan indications driven by misfolded proteins.

AC Immune to Host Webinar Highlighting its Innovative Morphomer™ Technology Platform and Pipeline

Retrieved on: 
Friday, March 26, 2021
Branches of biology, Alpha-synuclein, Lewy body dementia, Tau protein, Brachyury, Biology

During the webinar, members of the AC Immune Management and Research and Development Teams will discuss the unique benefits of the Companys innovative Morphomer technology platform, which accelerates the design, synthesis, and development of CNS-optimized, conformation-specific small molecules directed against pathological proteins.

Key Points: 
  • During the webinar, members of the AC Immune Management and Research and Development Teams will discuss the unique benefits of the Companys innovative Morphomer technology platform, which accelerates the design, synthesis, and development of CNS-optimized, conformation-specific small molecules directed against pathological proteins.
  • The platform has produced multiple clinically validated therapeutic and diagnostic candidates that bind selectively to target proteins intracellularly, at the earliest stages of disease.
  • The current Morphomer pipeline includes two clinical-stage diagnostic candidates (Tau-PET tracer and alpha-synuclein-PET tracer), and one therapeutic candidate that has completed Phase 1 (Morphomer Tau ACI-3024).
  • Following the formal presentations, there will be an interactive virtual roundtable discussion between the audience and the AC Immune Management and Research and Development Teams.

AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook

Retrieved on: 
Tuesday, March 23, 2021

Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: We began 2021 with strong momentum based on the effective execution of our multi-pronged clinical development growth strategy.

Key Points: 
  • Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: We began 2021 with strong momentum based on the effective execution of our multi-pronged clinical development growth strategy.
  • In parallel, we continue to collaborate with our global partners to advance our later-stage clinical programs toward key inflection points.
  • Looking forward in 2021, we expect to build upon our successes and continue innovating as a leader in precision medicine for neurodegenerative disease.
  • Primary completion of the second Phase 2 study in moderate AD patients is expected in Q2 2021.